The U.S. Food and Drug Administration (FDA) has approved Pfizer Inc. and BioNTech SE’s modified COVID-19 vaccine, which targets the LP.8.1 variant. This is a major step forward in the ongoing fight against COVID-19. The clearance marks a change in the agency’s vaccination approach by limiting vaccine access to particular high-risk groups.
Approval Details
The supplemental biologics license application (sBLA) for the firm’s LP.8.1-adapted monovalent COVID-19 vaccine, COMIRNATY® LP.8.1, has been approved by the FDA. Two different groups are covered by the approval.
- People 65 years of age and older,
- People between the ages of 5 and 64 who have at least one underlying medical condition that increases their likelihood of experiencing severe COVID-19 outcomes.
Read More: FDA grants approval for the blood cancer therapy of Pfizer
Science Behind
A thorough body of evidence demonstrating the Pfizer-BioNTech COVID-19 vaccination platform’s safety and effectiveness serves as the foundation for the FDA’s clearance. Clinical trial results that previously supported authorization for children aged 5 to 11 years are incorporated into the approval.
Enhanced Immune Response
Preclinical research shows that, in comparison to earlier formulations, the LP.8.1-adapted vaccine produces better immune responses against a number of circulating SARS-CoV-2 sublineages. The vaccine’s efficacy has increased against:
- Variant XFG
- Variant NB.1.8.1
- Other modern sublineages
These enhancements are a major step up from the businesses’ monovalent COVID-19 vaccines that were modified for JN.1 and KP.2.
GSK Secures Japan Orphan Drug Designation for Risvutatug Rezetecan in Small-Cell Lung Cancer
GSK’s risvutatug rezetecan has officially secured Orphan Drug Designation from Japan’s MHLW for the treatment of small-cell lung cancer (SCLC). Supported by durable response data […]
Technology and Development
Both firms worked together to produce the COVID-19 vaccines, which make use of BioNTech’s exclusive mRNA technology. For COMIRNATY® and its modified vaccines, BioNTech is the Marketing Authorization Holder in a number of jurisdictions, including:
- United States
- European Union
- United Kingdom
- Additional international markets
Additionally, the business has emergency use authorizations or comparable permissions in a number of other nations across the world.
Last Modified:
Graduated from the University of Kerala with B.Sc. Botany and Biotechnology. Attained Post-Graduation in Biotechnology from the Kerala University of Fisheries and Ocean Science (KUFOS) with the third rank. Conducted various seminars and attended major Science conferences. Done 6 months of internship in ICMR – National Institute of Nutrition, Hyderabad. 5 years of tutoring experience.
